Terms: = Liver cancer AND MSN, P26038, 4478, ENSG00000147065
46 results:
1. Tumor-targeted gypenoside nanodrug delivery system with double protective layers.
Lai Z; Bai F; Pu T; Li J; Wu L; Zhou Z; Yang N
J Cancer Res Ther; 2024 Apr; 20(2):684-694. PubMed ID: 38687941
[TBL] [Abstract] [Full Text] [Related]
2. Mesoporous Silicon Nanoparticles with liver-Targeting and pH-Response-Release Function Are Used for Targeted Drug Delivery in liver cancer Treatment.
Wei J; Tan Y; Bai Y; He J; Cao H; Guo J; Su Z
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473773
[TBL] [Abstract] [Full Text] [Related]
3. PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy.
Jiang L; Wang X; Raza F; Zhong H; Su J; Yuan WE; Qiu M
Biomater Sci; 2023 Jul; 11(15):5301-5319. PubMed ID: 37357799
[TBL] [Abstract] [Full Text] [Related]
4. liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets.
Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Valerio H; Dore GJ
J Viral Hepat; 2023 Jun; 30(6):520-529. PubMed ID: 36843500
[TBL] [Abstract] [Full Text] [Related]
5. Targeting UBR5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery.
Wang M; Ma X; Wang G; Song Y; Zhang M; Mai Z; Zhou B; Ye Y; Xia W
Cell Mol Biol Lett; 2022 Oct; 27(1):92. PubMed ID: 36224534
[TBL] [Abstract] [Full Text] [Related]
6. ALP-Activated Chemiluminescence PDT Nano-Platform for liver cancer-Specific Theranostics.
Fan N; Li P; Wu C; Wang X; Zhou Y; Tang B
ACS Appl Bio Mater; 2021 Feb; 4(2):1740-1748. PubMed ID: 35014520
[TBL] [Abstract] [Full Text] [Related]
7. Mitochondria-targeted mesoporous silica nanoparticles noncovalently modified with triphenylphosphonium cation: Physicochemical characteristics, cytotoxicity and intracellular uptake.
Ibragimova AR; Gabdrakhmanov DR; Valeeva FG; Vasileva LA; Sapunova AS; Voloshina AD; Saifina AF; Gubaidullin AT; Danilaev MP; Egorova SR; Tyryshkina AA; Lamberov AA; Khamatgalimov AR; Sibgatullina GV; Samigullin DV; Petrov KA; Zakharova LY; Sinyashin OG
Int J Pharm; 2021 Jul; 604():120776. PubMed ID: 34098055
[TBL] [Abstract] [Full Text] [Related]
8. Selenium-driven enhancement of synergistic cancer chemo-/radiotherapy by targeting nanotherapeutics.
Liu X; Yuan Z; Tang Z; Chen Q; Huang J; He L; Chen T
Biomater Sci; 2021 Jul; 9(13):4691-4700. PubMed ID: 34019044
[TBL] [Abstract] [Full Text] [Related]
9. Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis: A protocol for systematic review and meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Medicine (Baltimore); 2021 Jan; 100(2):e24172. PubMed ID: 33466191
[TBL] [Abstract] [Full Text] [Related]
10. Application of Abdominal Imaging Based on Nano Drug Delivery System for Diagnosis and Treatment of liver cancer.
Fan Z; Liu Q; Lu F; Dong Z; Gao P
J Nanosci Nanotechnol; 2021 Feb; 21(2):824-832. PubMed ID: 33183413
[TBL] [Abstract] [Full Text] [Related]
11. In vivo Targeting of liver cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract] [Full Text] [Related]
12. Short-term Outcomes of "Difficult" Laparoscopic liver Resection at Specialized Centers: Report From INSTALL (International Survey on Technical Aspects of Laparoscopic liver Resection)-2 on 4478 Patients.
Ibuki S; Hibi T; Tanabe M; Geller DA; Cherqui D; Wakabayashi G;
Ann Surg; 2022 May; 275(5):940-946. PubMed ID: 32889884
[TBL] [Abstract] [Full Text] [Related]
13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic imaging of hepatocellular carcinoma at community hospitals and their tertiary referral center in the era of LI-RADS: a quality assessment study.
Chan A; Sertic M; Sammon J; Kim TK; Jang HJ; Guimaraes L; O'Malley M; Khalili K
Abdom Radiol (NY); 2019 Dec; 44(12):4028-4036. PubMed ID: 31555846
[TBL] [Abstract] [Full Text] [Related]
15. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract] [Full Text] [Related]
16. [Evaluation of the Occurrence of Surgical Site Infection(SSI)after Hepatectomy in Elderly Patients with Hepatocellular Carcinoma(HCC)].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Kawai K; Inatome J; Murakami K; Naito A; Kagawa Y; Masuzawa T; Takeno A; Egawa C; Kato T; Tamura S; Murata K
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1668-1670. PubMed ID: 29394737
[TBL] [Abstract] [Full Text] [Related]
17. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract] [Full Text] [Related]
18. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract] [Full Text] [Related]
19. Quantitative and correlative biodistribution analysis of
Kramer L; Winter G; Baur B; Kuntz AJ; Kull T; Solbach C; Beer AJ; Lindén M
Nanoscale; 2017 Jul; 9(27):9743-9753. PubMed ID: 28678239
[TBL] [Abstract] [Full Text] [Related]
20. A smart pH-responsive nano-carrier as a drug delivery system for the targeted delivery of ursolic acid: suppresses cancer growth and metastasis by modulating P53/MMP-9/PTEN/CD44 mediated multiple signaling pathways.
Jiang K; Chi T; Li T; Zheng G; Fan L; Liu Y; Chen X; Chen S; Jia L; Shao J
Nanoscale; 2017 Jul; 9(27):9428-9439. PubMed ID: 28660943
[TBL] [Abstract] [Full Text] [Related]
[Next]
